OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 12 of 19

13 Common AEs Key Interactions/Notes Side Effects Palpitations, heart rate (HR)/blood pressure (BP), restlessness, dizziness, insomnia, mood changes, HA, dry mouth, diarrhea/ constipation Avoid MAOIs (within 14 days); avoid other sympathomimetics, alcohol, adrenergic neuron blockers, some anesthetics ~5% Common AEs Key Interactions/Notes Avg. Wt Loss vs. Placebo Injection site rxns, skin hyperpigmentation, nausea, HA, diarrhea, abd/ back pain, fatigue, upper respiratory tract infection (URTI), depression, spontaneous penile erection No major known interactions Varies: POMC/PCSK1 23% to 34%; LEPR ~10–13%; BBS ~7.9% HA, hypoglycemia, abd pain; weight Potentiates hypoglycemic agents ~4–14% (by baseline leptin) Hypertrichosis, edema, hyperglycemia, rash, fever, arthralgia CYP1A2/3A4 substrate; oxidation/sulfate metabolism No signif icant weight change (fat mass, lean mass)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026